<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131236">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02038777</url>
  </required_header>
  <id_info>
    <org_study_id>B1371005</org_study_id>
    <nct_id>NCT02038777</nct_id>
  </id_info>
  <brief_title>A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913, An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy Or Low-Dose Ara-C In Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients.
      PF-04449913 will be administered orally as a single agent in patients with select advanced
      hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and
      daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or high-risk
      MDS [Myelodysplastic Syndrome].
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>First cycle Dose Limiting Toxicities</measure>
    <time_frame>28 days after first dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective disease response</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related gene mutation (PD biomarkers)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable tumor Gli1 expression (PD Biomarkers)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Monotherapy Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 in combination with low dose ARA-C (LDAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Monotherapy Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Combination Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose ARA-C (LDAC)</intervention_name>
    <description>Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.</description>
    <arm_group_label>Combination Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Daunorubicin given using 60 mg/m2 for 3-days.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 100 mg/m2 on days 1 through 7.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with select advanced hematologic malignancies who are refractory, resistant
             or intolerant to prior therapies for monotherapy cohort.

          -  Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated
             for combination cohort.

          -  ECOG [Eastern Cooperative Oncology Group] performance status 0 to 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients with active CNS disease

          -  Patient with active malignancy with the exception of basal cell carcinoma, non
             melanoma skin cancer, carcinoma in situ cervical

          -  Patient has an active, life threatening or clinically significant uncontrolled
             systemic infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371005&amp;StudyName=A%20Study%20Of%20PF-04449913%20In%20Japanese%20Patients%20With%20Select%20Hematologic%20Malignancies</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
